Background
The risk of stricter price regulation in the pharmaceutical industry has led to pressure on the biotechnology stock prices. The pressure is also coming from the early signs of a tightening of the FDA's
Seagen: The New Oncology Hope
Summary
- In recent years, Seagen has undergone a transformation from a one-product company to a diversified player in the oncology drug market.
- The current conservative stock price based on the DCF model is $ 159.
- The valuation of the company's business as a target for the takeover is $ 246 per share.
I am the head of research for the pre-IPO and venture division of the investment bank. Prior to that, I have been working as a global equity research analyst in an investment bank for the past 5 years. My specialization are Biotechnology, Internet and Media. I Received my CFA Charter in 2017. Also, I am FRM Charter. Besides, I am the author of the Russian-language Telegram-channel (the link in the section Website URL).
Analyst’s Disclosure:I am/we are long BMRN, SGEN, VRTX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This is not investment advice. I am not an investment adviser. Before making any investment, please do your own research!
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.